Copyright
©The Author(s) 2025.
World J Exp Med. Dec 20, 2025; 15(4): 108702
Published online Dec 20, 2025. doi: 10.5493/wjem.v15.i4.108702
Published online Dec 20, 2025. doi: 10.5493/wjem.v15.i4.108702
Table 1 Demographic data and clinical profile of study participants, n (%)/mean ± SD
| Male (n = 6) | Female (n = 29) | Total (n = 35) | P value | ||
| Age (years) | 34.67 ± 10.58 | 35.24 ± 12.42 | 35.14 ± 11.98 | 0.92 | |
| Residence | 0.85 | ||||
| Local | 5 (83.33) | 25 (86.21) | 30 (85.71) | ||
| Regional | 1 (16.67) | 4 (13.79) | 5 (14.29) | ||
| Socio-economic status | 0.19 | ||||
| Upper | 1 (16.67) | 1 (3.45) | 2 (5.71) | ||
| Upper middle | 3 (50.00) | 11 (37.93) | 14 (40.00) | ||
| Lower middle | 1 (16.67) | 16 (55.17) | 17 (48.57) | ||
| Upper lower | 1 (16.67) | 1 (3.45) | 2 (5.71) | ||
| Occupation | < 0.01 | ||||
| Farmer | 1 (16.67) | 0 (0.00) | 1 (2.86) | ||
| Homemaker | 1 (16.67) | 21 (72.41) | 22 (62.86) | ||
| Student | 2 (33.33) | 7 (24.14) | 9 (25.71) | ||
| Business | 2 (33.33) | 0 (0.00) | 2 (5.71) | ||
| Teacher | 0 (0.00) | 1 (3.45) | 1 (2.86) | ||
| Chief complaints | 0.82 | ||||
| Headache | Yes | 5 (83.33) | 23 (79.31) | 28 (80.00) | |
| No | 1 (16.67) | 6 (20.69) | 7 (20.00) | ||
| Visual loss | Yes | 4 (66.67) | 24 (82.76) | 28 (80.00) | 0.37 |
| No | 2 (33.33) | 5 (17.24) | 7 (20.00) | ||
| Others (hormonal disturbances) | Yes | 5 (83.33) | 22 (75.86) | 27 (77.14) | 0.69 |
| No | 1 (16.67) | 7 (24.14) | 8 (22.86) | ||
Table 2 Retinal nerve fiber layer thickness (microns) in various tumor categories, mean ± SD
| Tumour category | Retinal nerve fiber layer preoperative | At discharge | After 1.5 months | After 3 months | After 6 months |
| Pituitary adenoma | 79.7 ± 27.9 | 80.7 ± 27.8 | 81.2 ± 27.5 | 87.6 ± 27.6 | 83.3 ± 28.2 |
| Craniopharyngioma | 102.0 ± 36.8 | 89.6 ± 34.2 | 67.5 ± 19.2 | 65.6 ± 18.2 | 67.8 ± 19.5 |
| Meningioma | 59.4 ± 12.9 | 62.8 ± 12.4 | 63.7 ± 11.1 | 60.0 ± 8.9 | 61.2 ± 9.9 |
| Others | 99.6 ± 32.2 | 89.1 ± 34.0 | 87.4 ± 31.8 | 86.9 ± 30.9 | 75.7 ± 27.0 |
Table 3 Distribution of retinal nerve fiber layer and ganglion cell complex thickness at baseline and follow-up visits, mean ± SD
| Retinal nerve fiber layer thickness (micron) | Pre-operative | At discharge | After 1.5 months | After 3 months | After 6 months |
| Superior | 110.19 ± 60.94 | 107.16 ± 43.84 | 97.28 ± 31.19 | 97.38 ± 29.16 | 98.54 ± 31.98 |
| Inferior | 107.25 ± 53.04 | 102.84 ± 34.25 | 95.87 ± 32.16 | 93.58 ± 32.07 | 95.97 ± 31.04 |
| Nasal | 68.04 ± 31.85 | 65.79 ± 22.88 | 61.53 ± 16.13 | 60.78 ± 15.41 | 61.83 ± 16.58 |
| Temporal | 51.51 ± 19.25 | 50.72 ± 12.29 | 51.16 ± 12.1 | 51.38 ± 10.32 | 51.91 ± 9.97 |
| Ganglion cell complex thickness (micron) | 65.67 ± 14.85 | 64.85 ± 15.23 | 65.26 ± 13.69 | 65.43 ± 15.59 | 66.19 ± 15.62 |
Table 4 Proportion of eyes with retinal nerve fiber layer and ganglion cell complex thinning, before and after surgery, n (%)
| Preoperative | P value | |||||
| Normal | Thinning | Total | ||||
| Postoperative | RNFL (superior) | Normal | 35 (50.7) | 4 (5.8) | 39 (56.5) | 0.25 |
| Thinning | 8 (11.6) | 22 (31.9) | 30 (43.5) | |||
| Total | 43 (62.3) | 26 (37.7) | 69 (100) | |||
| RNFL (inferior) | Normal | 33 (47.8) | 3 (4.3) | 36 (52.2) | < 0.05 | |
| Thinning | 12 (17.4) | 21 (30.4) | 33 (47.8) | |||
| Total | 45 (65.2) | 24 (34.8) | 69 (100) | |||
| RNFL (nasal) | Normal | 42 (60.9) | 6 (8.7) | 48 (69.6) | 0.22 | |
| Thinning | 11 (15.9) | 10 (14.5) | 21 (30.4) | |||
| Total | 53 (76.8) | 16 (23.2) | 69 (100) | |||
| RNFL (temporal) | Normal | 32 (46.4) | 16 (23.2) | 48 (69.6) | < 0.05 | |
| Thinning | 6 (8.7) | 15 (21.7) | 21 (30.4) | |||
| Total | 38 (55.1) | 31 (44.9) | 69 (100) | |||
| GCC | Normal | 20 (29.0) | 12 (17.4) | 32 (46.4) | 0.09 | |
| Thinning | 5 (7.2) | 32 (46.4) | 37 (53.6) | |||
| Total | 25 (36.2) | 44 (63.8) | 69 (100) | |||
Table 5 Association of visual impairment with retinal nerve fiber layer and ganglion cell complex thickness, at baseline and final follow-up, mean ± SD
| Mild visual impairment (6/6-6/18) | Moderate impairment (6/18-6/36) | Severe impairment to blind (6/36-3/60) | P value | ||
| Preoperative | |||||
| RNFL thickness in micron | Superior | 128.06 ± 65.91 | 98.17 ± 24.37 | 66.06 ± 18.34 | < 0.01 |
| Inferior | 123.41 ± 54.42 | 103.67 ± 24.42 | 64.76 ± 27.67 | < 0.01 | |
| Nasal | 74.96 ± 34.56 | 59.67 ± 18.14 | 52.29 ± 20.57 | < 0.05 | |
| Temporal | 55.89 ± 21.23 | 42.83 ± 7.81 | 42.7 ± 11.08 | < 0.05 | |
| Mean GCC thickness in micron | 70.5 ± 13.6 | 58 ± 10.02 | 55.29 ± 13.51 | < 0.01 | |
| Postoperative (six-month follow-up) | |||||
| RNFL thickness in micron | Superior | 105.98 ± 29.84 | 95.25 ± 28.06 | 63.18 ± 17.95 | < 0.01 |
| Inferior | 102.61 ± 27.51 | 101 ± 38.84 | 61.54 ± 23.1 | < 0.01 | |
| Nasal | 63.2 ± 15.28 | 69.75 ± 9.18 | 52.18 ± 21.64 | 0.08 | |
| Temporal | 53.2 ± 9.19 | 46.5 ± 8.18 | 47.54 ± 12.89 | 0.12 | |
| Mean GCC thickness in micron | 69.9 ± 12.67 | 67.25 ± 16.98 | 47.54 ± 16.26 | < 0.01 | |
Table 6 Univariate analysis of factors predictive of blindness
| Variables | Preoperative | Final postoperative | |||
| Cor (95%CI) | P value | Cor (95%CI) | P value | ||
| Age | 0.99 (0.93-1.06) | 0.915 | 1.00 (0.92-1.08) | 0.991 | |
| Duration of symptoms | 0.96 (0.86-1.06) | 0.45 | 0.98 (0.89-1.08) | 0.764 | |
| Preoperative mean RNFL thickness | Superior | 0.95 (0.92-0.98) | < 0.01 | 0.96 (0.94-0.99) | < 0.01 |
| Inferior | 0.96 (0.93-0.98) | < 0.01 | 0.96 (0.94-0.98) | < 0.01 | |
| Nasal | 0.97 (0.93-1.00) | 0.06 | 0.98 (0.95-1.01) | 0.273 | |
| Temporal | 0.93 (0.87-0.99) | < 0.05 | 0.95 (0.88-1.01) | 0.11 | |
| Preoperative mean GCC thickness | 0.95 (0.91-0.99) | < 0.05 | 0.95 (0.91-0.99) | < 0.05 | |
| Tumor volume | 1.00 (0.99-1.00) | 0.128 | 1.00 (0.99-1.00) | 0.09 | |
| Duration of surgery | 1.61 (0.95-2.75) | 0.078 | 1.57 (0.83-2.99) | 0.166 | |
| Surgical approach | 3.23 (0.55-18.96) | 0.194 | 4 (0.39-40.1) | 0.239 | |
- Citation: Parija S, Chakraborty K, Sahu RN, Nayak B, Rathod RS. Ganglion cell complex and retinal nerve fiber layer thickness in predicting visual outcome in brain tumors after surgery. World J Exp Med 2025; 15(4): 108702
- URL: https://www.wjgnet.com/2220-315X/full/v15/i4/108702.htm
- DOI: https://dx.doi.org/10.5493/wjem.v15.i4.108702
